--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------
03.03.2010
Berlin, 3 March 2010. Marseille-Kliniken AG (Prime Standard, ISIN DE 0007783003,
MKA) has appointed Claus Dobrowolski (53) and Axel Regenhardt (46) to the
Management Board. Claus Dobrowolski is to head Finance from 2 April 2010, while
Axel Regenhardt is to assume responsibility for a new function on the Management
Board with immediate effect, managing IT, Operations and Auditing at the listed
health services provider. Axel Hölzer, in charge of operating business at
Marseille-Kliniken AG since 2002, will remain CEO.
Claus Dobrowolski holds a degree in business administration and is currently in
an executive position at Sasol Germany as Director - Special Assignments. The
company is part of the South African Sasol Group, employs around 1,500 employees
in Germany and produces surfactants and their primary products, inorganic
speciality chemicals and olefins. Dobrowolski was a member of the Executive
Board at Sasol Wax International AG, the global leader in the field of paraffin
wax and paraffin related products, for seven years until March 2009 and as CFO
(Chief Financial Officer) was also responsible for strategy in addition to
finance.
IT specialist Axel Regenhardt has held a number of executive positions within
the group of companies in Marseille-Kliniken AG. In his previous position, he
was the Group´s general agent and the director of Business Service Management at
VDSE GmbH (an administration service provider for social institutions). The
company develops and implements custom IT solutions for care, rehabilitation and
acute care institutions operated by the health service provider.
By installing the new function on the Management Board, Marseille-Kliniken AG is
strengthening its business activities in the IT sector. The last few years have
seen the Group make substantial investments into software development. At the
moment, the Company owns more than 20 software solutions, which are deployed to
structure processes in companies providing services in the field of healthcare.
The focus of IT applications is on safeguarding and reviewing quality inside
care institutions. The Group is planning to enhance its activities in this
segment.
End of ad hoc release
Further inquiry note:
Hillermann Consulting
Christian Hillermann
Investor Relations for Marseille-Kliniken AG
Poststraße 14/16
20354 Hamburg
Germany
Tel.: +49-(0)40 / 320 279-10
Fax: +49-(0)40 / 320 279-114
www.hillermann-consulting.de
Marseille-Kliniken AG
Dr. Ute Buchheim
Friedrich-Ebert-Str. 65
33330 Gütersloh
Germany
Tel.: +49-(0)5241/90 39-35
Fax: +49-(0)5241/90 39-39
www.marseille-kliniken.com
end of announcement euro adhoc
--------------------------------------------------------------------------------
~
issuer: Marseille-Kliniken AG
Alte Jakobstraße 79/80
D-10709 Berlin
phone: +49 (0)30 246 32-400
FAX: +49 (0)30 246 32-401
mail: info@marseille-kliniken.de
WWW: http://www.marseille-kliniken.de
sector: Pharmaceuticals
ISIN: DE0007783003
indexes: CDAX, Classic All Share, Prime All Share
~
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Stuttgart, Düsseldorf, regulated dealing: Hamburg
language: English
http://www.ots.at/pressemappe/EASY_7994
*** OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER
INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT ***
OTS0285 2010-03-03/15:00
031500 Mär 10
OTB0014 0484
